Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.nature.com/articles/s41591-019-0628-7, but it redirected us to https://www.nature.com/articles/s41591-019-0628-7. The analysis below is for the second page.

Title[redir]:
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial | Nature Medicine
Description:
Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4–7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309 ). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21–41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 96,105,781 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

article, cancer, nature, google, scholar, data, patients, cas, urothelial, neoadjuvant, oncology, research, analysis, response, carcinoma, hospital, clinical, study, access, bladder, biomarkers, baseline, tumor, med, medical, medicine, atezolizumab, trial, department, fundinghonoraria, content, metastatic, phase, cells, treatment, chemotherapy, clin, university, extended, samples, information, change, published, biomarker, powles, muscleinvasive, immunotherapy, advanced, nat, immune,

Topics {✒️}

nature portfolio journals permissions reprints nature portfolio privacy policy advertising muscle-invasive bladder cancer muscle-invasive urothelial cancer social media transforming growth factor-β protocol development open-label nature+ nature 554 nature pieter-jan van dam research funding/honoraria european genome-phenome archive alejo rodriguez-vida pd-1/pd-l1 blockade albert font pous cisplatin-based neoadjuvant chemotherapy accession number ega-box-1336 universidad de sevilla pd-1/pd-l1 immunotherapy high-risk resectable melanoma refractory solid tumors platinum-treated locally advanced permissions springerlink instant access barts cancer institute netherlands cancer institute santiago de compostela van der heijden extended data fig advanced urothelial cancers urbano anido herranz maria jose mendez neoadjuvant pd-1 blockade pd-l1 blockade data monitoring committee author correspondence fibroblast activation protein hospital del mar resting memory cells operable urothelial carcinoma gene expression signatures metastatic urothelial carcinoma resectable lung cancer privacy ligand 1 pd-l1

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
         description:Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4–7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309 ). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21–41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
         datePublished:2019-11-04T00:00:00Z
         dateModified:2023-03-21T00:00:00Z
         pageStart:1706
         pageEnd:1714
         sameAs:https://doi.org/10.1038/s41591-019-0628-7
         keywords:
            Bladder cancer
            Predictive markers
            Biomedicine
            general
            Cancer Research
            Metabolic Diseases
            Infectious Diseases
            Molecular Medicine
            Neurosciences
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig3_HTML.png
         isPartOf:
            name:Nature Medicine
            issn:
               1546-170X
               1078-8956
            volumeNumber:25
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Thomas Powles
               url:http://orcid.org/0000-0001-7760-4724
               affiliation:
                     name:Queen Mary University of London
                     address:
                        name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Mark Kockx
               affiliation:
                     name:HistogeneX N.V.
                     address:
                        name:HistogeneX N.V., Wilrijk, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alejo Rodriguez-Vida
               affiliation:
                     name:Hospital del Mar
                     address:
                        name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ignacio Duran
               affiliation:
                     name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Simon J. Crabb
               url:http://orcid.org/0000-0003-3521-9064
               affiliation:
                     name:University of Southampton
                     address:
                        name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michiel S. Van Der Heijden
               affiliation:
                     name:The Netherlands Cancer Institute
                     address:
                        name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bernadett Szabados
               affiliation:
                     name:Queen Mary University of London
                     address:
                        name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Albert Font Pous
               affiliation:
                     name:Hospital Universitari Germans Trias i Pujol
                     address:
                        name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gwenaelle Gravis
               affiliation:
                     name:Institut Paoli-Calmettes
                     address:
                        name:Institut Paoli-Calmettes, Marseille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Urbano Anido Herranz
               url:http://orcid.org/0000-0003-0376-5642
               affiliation:
                     name:Hospital Clinico Universitario de Santiago
                     address:
                        name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Andrew Protheroe
               url:http://orcid.org/0000-0001-9413-0575
               affiliation:
                     name:Churchill Hospital
                     address:
                        name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alain Ravaud
               affiliation:
                     name:University of Bordeaux–CHU Bordeaux
                     address:
                        name:Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux–CHU Bordeaux, Bordeaux, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Denis Maillet
               affiliation:
                     name:Hospital Lyon Sud
                     address:
                        name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maria Jose Mendez
               url:http://orcid.org/0000-0002-7460-1859
               affiliation:
                     name:Reina Sofia University Hospital
                     address:
                        name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Cristina Suarez
               affiliation:
                     name:Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona
                     address:
                        name:Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mark Linch
               affiliation:
                     name:University College London Hospital
                     address:
                        name:Department of Medical Oncology, University College London Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Aaron Prendergast
               url:http://orcid.org/0000-0002-9668-6689
               affiliation:
                     name:Queen Mary University of London
                     address:
                        name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Pieter-Jan van Dam
               url:http://orcid.org/0000-0001-9074-8271
               affiliation:
                     name:HistogeneX N.V.
                     address:
                        name:HistogeneX N.V., Wilrijk, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Diana Stanoeva
               affiliation:
                     name:HistogeneX N.V.
                     address:
                        name:HistogeneX N.V., Wilrijk, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sofie Daelemans
               affiliation:
                     name:HistogeneX N.V.
                     address:
                        name:HistogeneX N.V., Wilrijk, Belgium
                        type:PostalAddress
                     type:Organization
                     name:University of Antwerp
                     address:
                        name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sanjeev Mariathasan
               affiliation:
                     name:Genentech
                     address:
                        name:Genentech, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joy S. Tea
               url:http://orcid.org/0000-0002-3395-149X
               affiliation:
                     name:Genentech
                     address:
                        name:Genentech, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kelly Mousa
               affiliation:
                     name:Queen Mary University of London
                     address:
                        name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Romain Banchereau
               affiliation:
                     name:Genentech
                     address:
                        name:Genentech, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Daniel Castellano
               affiliation:
                     name:Hospital 12 de Octubre
                     address:
                        name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
      description:Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4–7. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309 ). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21–41%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-β and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment. A single-arm multicenter phase 2 trial demonstrates clinical efficacy of neoadjuvant PD-L1 blockade in patients with resectable muscle-invasive bladder cancer ineligible for cisplatin and examines biomarkers associated with patient outcome.
      datePublished:2019-11-04T00:00:00Z
      dateModified:2023-03-21T00:00:00Z
      pageStart:1706
      pageEnd:1714
      sameAs:https://doi.org/10.1038/s41591-019-0628-7
      keywords:
         Bladder cancer
         Predictive markers
         Biomedicine
         general
         Cancer Research
         Metabolic Diseases
         Infectious Diseases
         Molecular Medicine
         Neurosciences
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-019-0628-7/MediaObjects/41591_2019_628_Fig3_HTML.png
      isPartOf:
         name:Nature Medicine
         issn:
            1546-170X
            1078-8956
         volumeNumber:25
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Thomas Powles
            url:http://orcid.org/0000-0001-7760-4724
            affiliation:
                  name:Queen Mary University of London
                  address:
                     name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Mark Kockx
            affiliation:
                  name:HistogeneX N.V.
                  address:
                     name:HistogeneX N.V., Wilrijk, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alejo Rodriguez-Vida
            affiliation:
                  name:Hospital del Mar
                  address:
                     name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ignacio Duran
            affiliation:
                  name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Simon J. Crabb
            url:http://orcid.org/0000-0003-3521-9064
            affiliation:
                  name:University of Southampton
                  address:
                     name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michiel S. Van Der Heijden
            affiliation:
                  name:The Netherlands Cancer Institute
                  address:
                     name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bernadett Szabados
            affiliation:
                  name:Queen Mary University of London
                  address:
                     name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Albert Font Pous
            affiliation:
                  name:Hospital Universitari Germans Trias i Pujol
                  address:
                     name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gwenaelle Gravis
            affiliation:
                  name:Institut Paoli-Calmettes
                  address:
                     name:Institut Paoli-Calmettes, Marseille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Urbano Anido Herranz
            url:http://orcid.org/0000-0003-0376-5642
            affiliation:
                  name:Hospital Clinico Universitario de Santiago
                  address:
                     name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Andrew Protheroe
            url:http://orcid.org/0000-0001-9413-0575
            affiliation:
                  name:Churchill Hospital
                  address:
                     name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alain Ravaud
            affiliation:
                  name:University of Bordeaux–CHU Bordeaux
                  address:
                     name:Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux–CHU Bordeaux, Bordeaux, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Denis Maillet
            affiliation:
                  name:Hospital Lyon Sud
                  address:
                     name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maria Jose Mendez
            url:http://orcid.org/0000-0002-7460-1859
            affiliation:
                  name:Reina Sofia University Hospital
                  address:
                     name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Cristina Suarez
            affiliation:
                  name:Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona
                  address:
                     name:Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mark Linch
            affiliation:
                  name:University College London Hospital
                  address:
                     name:Department of Medical Oncology, University College London Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Aaron Prendergast
            url:http://orcid.org/0000-0002-9668-6689
            affiliation:
                  name:Queen Mary University of London
                  address:
                     name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Pieter-Jan van Dam
            url:http://orcid.org/0000-0001-9074-8271
            affiliation:
                  name:HistogeneX N.V.
                  address:
                     name:HistogeneX N.V., Wilrijk, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Diana Stanoeva
            affiliation:
                  name:HistogeneX N.V.
                  address:
                     name:HistogeneX N.V., Wilrijk, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sofie Daelemans
            affiliation:
                  name:HistogeneX N.V.
                  address:
                     name:HistogeneX N.V., Wilrijk, Belgium
                     type:PostalAddress
                  type:Organization
                  name:University of Antwerp
                  address:
                     name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sanjeev Mariathasan
            affiliation:
                  name:Genentech
                  address:
                     name:Genentech, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joy S. Tea
            url:http://orcid.org/0000-0002-3395-149X
            affiliation:
                  name:Genentech
                  address:
                     name:Genentech, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kelly Mousa
            affiliation:
                  name:Queen Mary University of London
                  address:
                     name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Romain Banchereau
            affiliation:
                  name:Genentech
                  address:
                     name:Genentech, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Daniel Castellano
            affiliation:
                  name:Hospital 12 de Octubre
                  address:
                     name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Medicine
      issn:
         1546-170X
         1078-8956
      volumeNumber:25
Organization:
      name:Nature Publishing Group US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Queen Mary University of London
      address:
         name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
         type:PostalAddress
      name:HistogeneX N.V.
      address:
         name:HistogeneX N.V., Wilrijk, Belgium
         type:PostalAddress
      name:Hospital del Mar
      address:
         name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
         type:PostalAddress
      name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
      address:
         name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
         type:PostalAddress
      name:University of Southampton
      address:
         name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
         type:PostalAddress
      name:The Netherlands Cancer Institute
      address:
         name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
         type:PostalAddress
      name:Queen Mary University of London
      address:
         name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
         type:PostalAddress
      name:Hospital Universitari Germans Trias i Pujol
      address:
         name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
         type:PostalAddress
      name:Institut Paoli-Calmettes
      address:
         name:Institut Paoli-Calmettes, Marseille, France
         type:PostalAddress
      name:Hospital Clinico Universitario de Santiago
      address:
         name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
         type:PostalAddress
      name:Churchill Hospital
      address:
         name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
         type:PostalAddress
      name:University of Bordeaux–CHU Bordeaux
      address:
         name:Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux–CHU Bordeaux, Bordeaux, France
         type:PostalAddress
      name:Hospital Lyon Sud
      address:
         name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
         type:PostalAddress
      name:Reina Sofia University Hospital
      address:
         name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
         type:PostalAddress
      name:Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona
      address:
         name:Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
         type:PostalAddress
      name:University College London Hospital
      address:
         name:Department of Medical Oncology, University College London Hospital, London, UK
         type:PostalAddress
      name:Queen Mary University of London
      address:
         name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
         type:PostalAddress
      name:HistogeneX N.V.
      address:
         name:HistogeneX N.V., Wilrijk, Belgium
         type:PostalAddress
      name:HistogeneX N.V.
      address:
         name:HistogeneX N.V., Wilrijk, Belgium
         type:PostalAddress
      name:HistogeneX N.V.
      address:
         name:HistogeneX N.V., Wilrijk, Belgium
         type:PostalAddress
      name:University of Antwerp
      address:
         name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
         type:PostalAddress
      name:Genentech
      address:
         name:Genentech, San Francisco, USA
         type:PostalAddress
      name:Genentech
      address:
         name:Genentech, San Francisco, USA
         type:PostalAddress
      name:Queen Mary University of London
      address:
         name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
         type:PostalAddress
      name:Genentech
      address:
         name:Genentech, San Francisco, USA
         type:PostalAddress
      name:Hospital 12 de Octubre
      address:
         name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Thomas Powles
      url:http://orcid.org/0000-0001-7760-4724
      affiliation:
            name:Queen Mary University of London
            address:
               name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Mark Kockx
      affiliation:
            name:HistogeneX N.V.
            address:
               name:HistogeneX N.V., Wilrijk, Belgium
               type:PostalAddress
            type:Organization
      name:Alejo Rodriguez-Vida
      affiliation:
            name:Hospital del Mar
            address:
               name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:Ignacio Duran
      affiliation:
            name:IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla
            address:
               name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
               type:PostalAddress
            type:Organization
      name:Simon J. Crabb
      url:http://orcid.org/0000-0003-3521-9064
      affiliation:
            name:University of Southampton
            address:
               name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
               type:PostalAddress
            type:Organization
      name:Michiel S. Van Der Heijden
      affiliation:
            name:The Netherlands Cancer Institute
            address:
               name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
               type:PostalAddress
            type:Organization
      name:Bernadett Szabados
      affiliation:
            name:Queen Mary University of London
            address:
               name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
               type:PostalAddress
            type:Organization
      name:Albert Font Pous
      affiliation:
            name:Hospital Universitari Germans Trias i Pujol
            address:
               name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
               type:PostalAddress
            type:Organization
      name:Gwenaelle Gravis
      affiliation:
            name:Institut Paoli-Calmettes
            address:
               name:Institut Paoli-Calmettes, Marseille, France
               type:PostalAddress
            type:Organization
      name:Urbano Anido Herranz
      url:http://orcid.org/0000-0003-0376-5642
      affiliation:
            name:Hospital Clinico Universitario de Santiago
            address:
               name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
               type:PostalAddress
            type:Organization
      name:Andrew Protheroe
      url:http://orcid.org/0000-0001-9413-0575
      affiliation:
            name:Churchill Hospital
            address:
               name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
               type:PostalAddress
            type:Organization
      name:Alain Ravaud
      affiliation:
            name:University of Bordeaux–CHU Bordeaux
            address:
               name:Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux–CHU Bordeaux, Bordeaux, France
               type:PostalAddress
            type:Organization
      name:Denis Maillet
      affiliation:
            name:Hospital Lyon Sud
            address:
               name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
               type:PostalAddress
            type:Organization
      name:Maria Jose Mendez
      url:http://orcid.org/0000-0002-7460-1859
      affiliation:
            name:Reina Sofia University Hospital
            address:
               name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
               type:PostalAddress
            type:Organization
      name:Cristina Suarez
      affiliation:
            name:Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona
            address:
               name:Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:Mark Linch
      affiliation:
            name:University College London Hospital
            address:
               name:Department of Medical Oncology, University College London Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:Aaron Prendergast
      url:http://orcid.org/0000-0002-9668-6689
      affiliation:
            name:Queen Mary University of London
            address:
               name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
               type:PostalAddress
            type:Organization
      name:Pieter-Jan van Dam
      url:http://orcid.org/0000-0001-9074-8271
      affiliation:
            name:HistogeneX N.V.
            address:
               name:HistogeneX N.V., Wilrijk, Belgium
               type:PostalAddress
            type:Organization
      name:Diana Stanoeva
      affiliation:
            name:HistogeneX N.V.
            address:
               name:HistogeneX N.V., Wilrijk, Belgium
               type:PostalAddress
            type:Organization
      name:Sofie Daelemans
      affiliation:
            name:HistogeneX N.V.
            address:
               name:HistogeneX N.V., Wilrijk, Belgium
               type:PostalAddress
            type:Organization
            name:University of Antwerp
            address:
               name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
               type:PostalAddress
            type:Organization
      name:Sanjeev Mariathasan
      affiliation:
            name:Genentech
            address:
               name:Genentech, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Joy S. Tea
      url:http://orcid.org/0000-0002-3395-149X
      affiliation:
            name:Genentech
            address:
               name:Genentech, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Kelly Mousa
      affiliation:
            name:Queen Mary University of London
            address:
               name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
               type:PostalAddress
            type:Organization
      name:Romain Banchereau
      affiliation:
            name:Genentech
            address:
               name:Genentech, San Francisco, USA
               type:PostalAddress
            type:Organization
      name:Daniel Castellano
      affiliation:
            name:Hospital 12 de Octubre
            address:
               name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
      name:HistogeneX N.V., Wilrijk, Belgium
      name:Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
      name:Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla, Seville, Spain
      name:Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK
      name:Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
      name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
      name:Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol, Badalona, Spain
      name:Institut Paoli-Calmettes, Marseille, France
      name:Department of Medical Oncology, Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain
      name:Department of Medical Oncology, Churchill Hospital, Oxford, UK
      name:Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux–CHU Bordeaux, Bordeaux, France
      name:Department of Medical Oncology, Hospital Lyon Sud, Lyon, France
      name:Department of Medical Oncology, Reina Sofia University Hospital, Cordoba, Spain
      name:Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
      name:Department of Medical Oncology, University College London Hospital, London, UK
      name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
      name:HistogeneX N.V., Wilrijk, Belgium
      name:HistogeneX N.V., Wilrijk, Belgium
      name:HistogeneX N.V., Wilrijk, Belgium
      name:Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium
      name:Genentech, San Francisco, USA
      name:Genentech, San Francisco, USA
      name:Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK
      name:Genentech, San Francisco, USA
      name:Department of Medical Oncology, Hospital 12 de Octubre, Madrid, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(289)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

5.4s.